Nureca Limited has informed the exchange regarding appointment of Chief Financial Officer (CFO).
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Ltd reported FY26 results with revenue of Rs 1,472.10 million, up 28% from Rs 1,146.40 million in FY25. The company returned to profit with net profit after tax of Rs 2.97 million versus a loss of Rs 6.68 million in the previous year. However, Q4 FY26 showed a loss of Rs 61.52 million mainly due to a Rs 83.37 million fair value loss on investments. The Board approved appointment of Mr. Chander Kant as new CFO effective June 27, 2026, promoted internally from Manager Finance, following the resignation of Mr. Naresh Gupta who leaves on June 26, 2026. Additionally, Ms. Smita Goyal (related to existing promoters Saurabh and Aryan Goyal) was appointed as Additional Director and Whole Time Director. The Board also approved Rs 100 crore capex for expanding manufacturing of medical devices and healthcare products at their Derabassi plant, plus land purchase for future expansion.
The company achieved a turnaround to profitability in FY26 with strong revenue growth, which is positive for shareholders. The seamless internal CFO transition minimises disruption. However, the appointment of another promoter family member to the board may raise governance concerns for minority investors as the board becomes more family-concentrated.